News
ASND
147.16
+1.33%
1.93
Weekly Report: what happened at ASND last week (0408-0412)?
Weekly Report · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)
TipRanks · 4d ago
Ascendis Pharma A/S Outlines Financial Strategy
TipRanks · 5d ago
Weekly Report: what happened at ASND last week (0401-0405)?
Weekly Report · 04/08 09:29
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio, A Seattle-Suzhou ADC Biotech, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, for autoimmune and inflammatory dermatologic diseases. Shanghai's Visen Pharma announced plans to stage an IPO on the Hong Kong Exchange.
Seeking Alpha · 04/07 10:30
Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S
Ascendis Pharma A/S' price-to-sales ratio of 29.2x is higher than the Biotech industry average. The company's revenues are expected to grow by 65% over the next three years. However, the company's forecast growth is lower than the industry as a whole.
Simply Wall St · 04/05 11:40
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 44.46% on an annualized basis. Currently, Ascendis Pharma has a market capitalization of $8.28 billion. If an investor bought $100 of ASND stock 10 years ago, it would be worth $8,187.29 today.
Benzinga · 04/03 17:00
Ascendis Pharma Price Target Raised to $167.00/Share From $165.00 by JP Morgan
Dow Jones · 04/02 14:58
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Dow Jones · 04/02 14:58
JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $167
Benzinga · 04/02 14:47
Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald
Dow Jones · 04/01 12:45
Weekly Report: what happened at ASND last week (0325-0329)?
Weekly Report · 04/01 09:29
Ascendis Pharma Updates Share Capital Structure
TipRanks · 03/27 21:27
GOP committee opposes cannabis banking bill; calls marijuana 'gateway drug'
House GOP committee opposes cannabis banking bill; calls marijuana 'gateway drug' The committee's policy guide says marijuana is a dangerous, addictive drug. The group says violent crime has increased in four states that have legalized marijuana for recreational purposes. Last week, cannabis stocks rallied on support for the SAFER Banking Act.
Seeking Alpha · 03/26 15:34
Americans overwhelmingly support cannabis banking reform - poll
Americans overwhelmingly support cannabis banking reform. A recent poll from the American Bankers Association found 63% of Americans favor allowing cannabis businesses access to the U.S. Financial system. 36% of respondents strongly support Congress passing cannabis banking legislation in states where marijuana has been legalized.
Seeking Alpha · 03/25 19:06
Weekly Report: what happened at ASND last week (0318-0322)?
Weekly Report · 03/25 09:30
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
NASDAQ · 03/22 11:47
Weekly Report: what happened at ASND last week (0311-0315)?
Weekly Report · 03/18 09:29
Ascendis Pharma Price Target Raised to $260.00/Share From $196.00 by Wells Fargo
Dow Jones · 03/15 12:51
Ascendis Pharma Is Maintained at Overweight by Wells Fargo
Dow Jones · 03/15 12:51
More
Webull provides a variety of real-time ASND stock news. You can receive the latest news about Ascendis Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ASND
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).